Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Mayur YC, Peters GJ, Prasad VV, Lemo C, Sathish NK. Design of new drug molecules to be used in reversing multidrug resistance in cancer cells. Curr. Cancer Drug Targets 9(3), 298–306 (2009).
  Medline CASGoogle Scholar
• 2 Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11(4), 265–283 (2000).
  Medline CASGoogle Scholar
• 3 Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr. Med. Chem. 19(13), 1946–2025 (2012).
  Medline CASGoogle Scholar
• 4 Falasca M, Linton KJ. Investigational ABC transporter inhibitors. Expert Opin. Investig. Drugs 21(5), 657–666 (2012).
  Medline CASGoogle Scholar
• 5 Yuan TZ, Zhang HH, Lin XL et al. MicroRNA-125b reverses the multidrug resistance of nasopharyngeal carcinoma cells via targeting of Bcl-2. Mol. Med. Rep. 15(4), 2223–2228 (2017).
  Medline CASGoogle Scholar
• 6 An X, Sarmiento C, Tan T, Zhu H. Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm. Sin. B 7(1), 38–51 (2017).
  MedlineGoogle Scholar
• 7 He M, Wei MJ. Reversing multidrug resistance by tyrosine kinase inhibitors. Chin. J. Cancer 31(3), 126–133 (2012).
  Medline CASGoogle Scholar
• 8 Li W, Zhang H, Assaraf YG et al. Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug Resist. Updat. 27, 14–29 (2016). • Introduction of ABC transporters in multidrug resistance.
  Medline CASGoogle Scholar
• 9 Fan YF, Zhang W, Zeng L et al. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Cancer Lett. 421, 186–198 (2018).
  Medline CASGoogle Scholar
• 10 Rogan AM, Hamilton TC, Young RC, Klecker RJ, Ozols RF. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224(4652), 994–996 (1984).
  Medline CASGoogle Scholar
• 11 Ferreira RJ, Baptista R, Moreno A et al. Optimizing the flavanone core toward new selective nitrogen-containing modulators of ABC transporters. Future Med. Chem. 10(7), 725–741 (2018).
  CASGoogle Scholar
• 12 Baptista R, Ferreira RJ, Dos SD, Fernandes MX, Ferreira MJ. Optimizing the macrocyclic diterpenic core toward the reversal of multidrug resistance in cancer. Future Med. Chem. 8(6), 629–645 (2016).
  CASGoogle Scholar
• 13 Kathawala RJ, Gupta P, Ashby CJ, Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist. Updat. 18, 1–17 (2015).
  MedlineGoogle Scholar
• 14 Shukla S, Chen ZS, Ambudkar SV. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist. Updat. 15(1–2), 70–80 (2012).
  Medline CASGoogle Scholar
• 15 Shen F, Bailey BJ, Chu S et al. Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells. J. Pharmacol. Exp. Ther. 330(2), 423–429 (2009).
  Medline CASGoogle Scholar
• 16 Korde CS, Sridharan G, Gadbail A, Poornima V. Nitric oxide and oral cancer: a review. Oral Oncol. 48(6), 475–483 (2012).
  Medline CASGoogle Scholar
• 17 De Bels D, Corazza F, Germonpre P, Balestra C. The normobaric oxygen paradox: a novel way to administer oxygen as an adjuvant treatment for cancer? Med. Hypotheses. 76(4), 467–470 (2011).
  Medline CASGoogle Scholar
• 18 Hellmich MR, Szabo C. Hydrogen sulfide and cancer. Handb. Exp. Pharmacol. 230, 233–241 (2015).
  Medline CASGoogle Scholar
• 19 Vitek L, Gbelcova H, Muchova L et al. Antiproliferative effects of carbon monoxide on pancreatic cancer. Dig. Liver Dis. 46(4), 369–375 (2014).
  Medline CASGoogle Scholar
• 20 Oliveira C, Benfeito S, Fernandes C, Cagide F, Silva T, Borges F. NO and HNO donors, nitrones, and nitroxides: past, present, and future. Med. Res. Rev. 38(4), 1159–1187 (2018).
  MedlineGoogle Scholar
• 21 Ohta S. Recent progress toward hydrogen medicine: potential of molecular hydrogen for preventive and therapeutic applications. Curr. Pharm. Des. 17(22), 2241–2252 (2011).
  Medline CASGoogle Scholar
• 22 Choudhari SK, Chaudhary M, Bagde S, Gadbail AR, Joshi V. Nitric oxide and cancer: a review. World J. Surg. Oncol. 11, 118 (2013).
  MedlineGoogle Scholar
• 23 Teas J, Cunningham JE, Cone L et al. Can hyperbaric oxygen therapy reduce breast cancer treatment-related lymphedema? A pilot study. J. Womens Health (Larchmt.) 13(9), 1008–1018 (2004).
  MedlineGoogle Scholar
• 24 Flannigan KL, Wallace JL. Hydrogen sulfide-based anti-inflammatory and chemopreventive therapies: an experimental approach. Curr. Pharm. Des. 21(21), 3012–3022 (2015).
  Medline CASGoogle Scholar
• 25 Wang R. Gasotransmitters: growing pains and joys. Trends Biochem. Sci. 39(5), 227–232 (2014).
  Medline CASGoogle Scholar
• 26 Mustafa AK, Gadalla MM, Snyder SH. Signaling by gasotransmitters. Sci. Signal. 2(68), e2 (2009).
  Google Scholar
• 27 Chinta KC, Saini V, Glasgow JN et al. The emerging role of gasotransmitters in the pathogenesis of tuberculosis. Nitric Oxide 59, 28–41 (2016).
  Medline CASGoogle Scholar
• 28 Dallas ML. Gaseous regulation of Ca²⁺ homeostasis; for better or worse? J. Physiol. 594(15), 4117–4118 (2016).
  Medline CASGoogle Scholar
• 29 Chen J, Shangguan ZP, Zheng HL. The function of hydrogen sulphide in iron availability: sulfur nutrient or signaling molecule? Plant Signal. Behav. 11(6), e1132967 (2016).
  MedlineGoogle Scholar
• 30 Iijima M, Gombodorj N, Tachibana Y et al. Development of single nanometer-sized ultrafine oxygen bubbles to overcome the hypoxia-induced resistance to radiation therapy via the suppression of hypoxia-inducible factor 1 alpha. Int. J. Oncol. 52(3), 679–686 (2018).
  Medline CASGoogle Scholar
• 31 Reynolds MM, Witzeling SD, Damodaran VB et al. Applications for nitric oxide in halting proliferation of tumor cells. Biochem. Biophys. Res. Commun. 431(4), 647–651 (2013).
  Medline CASGoogle Scholar
• 32 Shao L, Gu YY, Jiang CH et al. Carbon monoxide releasing molecule-2 suppresses proliferation, migration, invasion, and promotes apoptosis in non-small cell lung cancer Calu-3 cells. Eur. Rev. Med. Pharmacol. Sci. 22(7), 1948–1957 (2018).
  Medline CASGoogle Scholar
• 33 Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 23(5), 537–548 (2009).
  Medline CASGoogle Scholar
• 34 Yttersian SK, Tveitaras MK, Lu N et al. Oxygen-dependent regulation of tumor growth and metastasis in human breast cancer xenografts. PLoS ONE 12(8), e183254 (2017).
  Google Scholar
• 35 Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin. Oncol. 28(2; Suppl. 8), 29–35 (2001).
  Medline CASGoogle Scholar
• 36 Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl Cancer Inst. 93(4), 266–276 (2001).
  Medline CASGoogle Scholar
• 37 Carmeliet P, Dor Y, Herbert JM et al. Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394(6692), 485–490 (1998).
  Medline CASGoogle Scholar
• 38 Talks KL, Turley H, Gatter KC et al. The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157(2), 411–421 (2000).
  Medline CASGoogle Scholar
• 39 Fukuda K, Hibiya Y, Mutoh M, Koshiji M, Akao S, Fujiwara H. Inhibition of activator protein 1 activity by berberine in human hepatoma cells. Planta Med. 65(4), 381–383 (1999).
  Medline CASGoogle Scholar
• 40 Xu L, Wang X, Wang J et al. Hypoxia-induced secretion of IL-10 from adipose-derived mesenchymal stem cell promotes growth and cancer stem cell properties of Burkitt lymphoma. Tumour Biol. 37(6), 7835–7842 (2016).
  Medline CASGoogle Scholar
• 41 Wartenberg M, Ling FC, Muschen M et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 17(3), 503–505 (2003).
  Medline CASGoogle Scholar
• 42 Xie G, Liu Y, Yao Q et al. Hypoxia-induced angiotensin II by the lactate-chymase-dependent mechanism mediates radioresistance of hypoxic tumor cells. Sci. Rep. 7, 42396 (2017).
  Medline CASGoogle Scholar
• 43 Bahr O, Wick W, Weller M. Modulation of MDR/MRP by wild-type and mutant p53. J. Clin. Invest. 107(5), 643–646 (2001).
  Medline CASGoogle Scholar
• 44 Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res. 41(1), 73–81 (1981).
  Medline CASGoogle Scholar
• 45 Wada Y, Hirose K, Harada T et al. Impact of oxygen status on 10B-BPA uptake into human glioblastoma cells, referring to significance in boron neutron capture therapy. J. Radiat. Res. 59(2), 122–128 (2018).
  Medline CASGoogle Scholar
• 46 Zitta K, Meybohm P, Bein B et al. Salicylic acid induces apoptosis in colon carcinoma cells grown in-vitro: influence of oxygen and salicylic acid concentration. Exp. Cell Res. 318(7), 828–834 (2012).
  Medline CASGoogle Scholar
• 47 Pinzon-Daza ML, Cuellar-Saenz Y, Nualart F et al. Oxidative stress promotes doxorubicin-induced Pgp and BCRP expression in colon cancer cells under hypoxic conditions. J. Cell. Biochem. 118(7), 1868–1878 (2017).
  Medline CASGoogle Scholar
• 48 Li W, Li J, Wang R, Xie H, Jia Z. MDR1 will play a key role in pharmacokinetic changes under hypoxia at high altitude and its potential regulatory networks. Drug Metab. Rev. 47(2), 191–198 (2015).
  Medline CASGoogle Scholar
• 49 Fetsch PA, Abati A, Litman T et al. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett. 235(1), 84–92 (2006).
  Medline CASGoogle Scholar
• 50 Krishnamurthy P, Ross DD, Nakanishi T et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem. 279(23), 24218–24225 (2004).
  Medline CASGoogle Scholar
• 51 Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11(6), 393–410 (2011).
  Medline CASGoogle Scholar
• 52 Huang L, Boling W, Zhang JH. Hyperbaric oxygen therapy as adjunctive strategy in treatment of glioblastoma multiforme. Med. Gas Res. 8(1), 24–28 (2018).
  Medline CASGoogle Scholar
• 53 Eisenbrey JR, Shraim R, Liu JB et al. Sensitization of hypoxic tumors to radiation therapy using ultrasound-sensitive oxygen microbubbles. Int. J. Radiat. Oncol. Biol. Phys. 101(1), 88–96 (2018).
  Medline CASGoogle Scholar
• 54 Chen J, Luo H, Liu Y et al. Oxygen-self-produced nanoplatform for relieving hypoxia and breaking resistance to sonodynamic treatment of pancreatic cancer. ACS Nano 11(12), 12849–12862 (2017).
  Medline CASGoogle Scholar
• 55 Li F, Mei H, Gao Y et al. Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer. Biomaterials 145, 56–71 (2017). • Liposomal complexes of oxygen co-delivery with chemotherapeutic agent is able to reverse multidrug resistance.
  Medline CASGoogle Scholar
• 56 Mungrue IN, Bredt DS, Stewart DJ, Husain M. From molecules to mammals: what's NOS got to do with it? Acta Physiol. Scand. 179(2), 123–135 (2003).
  Medline CASGoogle Scholar
• 57 Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem. J. 298(Pt 2), 249–258 (1994).
  Medline CASGoogle Scholar
• 58 Yang L, Wang Y, Guo L, Wang L, Chen W, Shi B. The expression and correlation of iNOS and p53 in oral squamous cell carcinoma. Biomed. Res. Int. 2015, 637853 (2015).
  MedlineGoogle Scholar
• 59 Yang M, Li H, Li Y, Ruan Y, Quan C. Identification of genes and pathways associated with MDR in MCF-7/MDR breast cancer cells by RNA-seq analysis. Mol. Med. Rep. 17(5), 6211–6226 (2018).
  Medline CASGoogle Scholar
• 60 Yu S, Jia L, Zhang Y et al. Increased expression of activated endothelial nitric oxide synthase contributes to antiandrogen resistance in prostate cancer cells by suppressing androgen receptor transactivation. Cancer Lett. 328(1), 83–94 (2013).
  Medline CASGoogle Scholar
• 61 Matsunaga T, Yamaji Y, Tomokuni T et al. Nitric oxide confers cisplatin resistance in human lung cancer cells through upregulation of aldo-keto reductase 1B10 and proteasome. Free Radic. Res. 48(11), 1371–1385 (2014).
  Medline CASGoogle Scholar
• 62 Li Y, Ma C, Shi X et al. Effect of nitric oxide synthase on multiple drug resistance is related to Wnt signaling in non-small cell lung cancer. Oncol. Rep. 32(4), 1703–1708 (2014).
  Medline CASGoogle Scholar
• 63 Wang J, Hussain SP. NO* and pancreatic cancer: a complex interaction with therapeutic potential. Antioxid. Redox Signal. 26(17), 1000–1008 (2017).
  Medline CASGoogle Scholar
• 64 Tran AN, Boyd NH, Walker K, Hjelmeland AB. NOS expression and NO function in glioma and implications for patient therapies. Antioxid. Redox Signal. 26(17), 986–999 (2017).
  Medline CASGoogle Scholar
• 65 Walsh EM, Keane MM, Wink DA, Callagy G, Glynn SA. Review of triple negative breast cancer and the impact of inducible nitric oxide synthase on tumor biology and patient outcomes. Crit. Rev. Oncog. 21(5–6), 333–351 (2016).
  MedlineGoogle Scholar
• 66 Kumar A, Ehrenshaft M, Tokar EJ, Mason RP, Sinha BK. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells. Biochim. Biophys. Acta 1860(7), 1519–1527 (2016).
  Medline CASGoogle Scholar
• 67 Sharma NK, Kumar A, Kumari A et al. Nitric oxide down-regulates topoisomerase I and induces camptothecin resistance in human breast MCF-7 tumor cells. PLoS ONE 10(11), e141897 (2015).
  MedlineGoogle Scholar
• 68 Chanvorachote P, Pongrakhananon V, Chunhacha P. Prolonged nitric oxide exposure enhances anoikis resistance and migration through epithelial-mesenchymal transition and caveolin-1 upregulation. Biomed. Res. Int. 2014, 941359 (2014).
  MedlineGoogle Scholar
• 69 Sinha BK, Kumar A, Bhattacharjee S, Espey MG, Mason RP. Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells. J. Pharmacol. Exp. Ther. 347(3), 607–614 (2013).
  Medline CASGoogle Scholar
• 70 Huang Z, Fu J, Zhang Y. Nitric oxide donor-based cancer therapy: advances and prospects. J. Med. Chem. 60(18), 7617–7635 (2017).
  Medline CASGoogle Scholar
• 71 Davila-Gonzalez D, Choi DS, Rosato RR et al. Pharmacological inhibition of NOS activates ASK1/JNK pathway augmenting docetaxel-mediated apoptosis in triple-negative breast cancer. Clin. Cancer Res. 24(5), 1152–1162 (2018).
  MedlineGoogle Scholar
• 72 Fahey JM, Stancill JS, Smith BC, Girotti AW. Nitric oxide antagonism to glioblastoma photodynamic therapy and mitigation thereof by BET bromodomain inhibitor JQ1. J. Biol. Chem. 293(14), 5345–5359 (2018).
  Medline CASGoogle Scholar
• 73 Fahey JM, Girotti AW. Nitric oxide-mediated resistance to photodynamic therapy in a human breast tumor xenograft model: improved outcome with NOS2 inhibitors. Nitric Oxide 62, 52–61 (2017).
  Medline CASGoogle Scholar
• 74 Yin M, Tan S, Bao Y, Zhang Z. Enhanced tumor therapy via drug co-delivery and in situ vascular-promoting strategy. J. Control. Release 258, 108–120 (2017).
  Medline CASGoogle Scholar
• 75 Ojeda PG, Wang CK, Craik DJ. Chlorotoxin: structure, activity, and potential uses in cancer therapy. Biopolymers 106(1), 25–36 (2016).
  Medline CASGoogle Scholar
• 76 Wiranowska M, Colina LO, Johnson JO. Clathrin-mediated entry and cellular localization of chlorotoxin in human glioma. Cancer Cell Int. 11, 27 (2011).
  Medline CASGoogle Scholar
• 77 Safdar S, Payne CA, Tu NH, Taite LJ. Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity. Biotechnol. Bioeng. 110(4), 1211–1220 (2013).
  Medline CASGoogle Scholar
• 78 Oronsky B, Scicinski J, Ning S et al. Rockets, radiosensitizers, and RRx-001: an origin story part I. Discov. Med. 21(115), 173–180 (2016).
  MedlineGoogle Scholar
• 79 Oronsky B, Scicinski J, Ning S et al. RRx-001, a novel dinitroazetidine radiosensitizer. Invest. New Drugs 34(3), 371–377 (2016).
  Medline CASGoogle Scholar
• 80 Scicinski J, Fisher G, Carter C et al. The development Of RRx-001, a novel nitric-oxide-mediated epigenetically active anticancer agent. Redox Biol. 5, 422 (2015).
  MedlineGoogle Scholar
• 81 Brzezniak C, Oronsky B, Aggarwal R. A complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets. Eur. Urol. 73(2), 306–307 (2018). •• RRx-001 is a promising drug candidate with NO releasing property, and it is now under multiple clinical trials.
  MedlineGoogle Scholar
• 82 Cottrill H, Cason S, Caroen S, Oronsky B, Donaldson E. A recurrent platinum refractory ovarian cancer patient with a partial response after RRx-001 resensitization to platinum doublet. J. Investig. Med. High Impact Case Rep. 6, 1559742064 (2018).
  Google Scholar
• 83 Oronsky B, Paulmurugan R, Foygel K et al. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opin. Investig. Drugs 26(1), 109–119 (2017).
  Medline CASGoogle Scholar
• 84 Brzezniak C, Oronsky B, Scicinski J et al. Conversion of platinum-etoposide-resistant to sensitive SCLC after treatment with the Epi-Immunotherapeutic RRx-001: a case report. Oncol. Res. Treat. 39(11), 720–723 (2016).
  Medline CASGoogle Scholar
• 85 Oronsky B, Caroen S, Zeman K et al. A partial response to reintroduced chemotherapy in a resistant small cell lung cancer patient after priming with RRx-001. Clin. Med. Insights Oncol. 10, 105–108 (2016).
  MedlineGoogle Scholar
• 86 Weyerbrock A, Osterberg N, Psarras N et al. JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas. Neurosurgery 70(2), 497–510, 510 (2012).
  MedlineGoogle Scholar
• 87 Kiziltepe T, Anderson KC, Kutok JL et al. JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo. J. Pharm. Pharmacol. 62(1), 145–151 (2010).
  Medline CASGoogle Scholar
• 88 Simeone AM, McMurtry V, Nieves-Alicea R et al. TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells. Breast Cancer Res. 10(3), R44 (2008).
  MedlineGoogle Scholar
• 89 Qiu M, Chen L, Tan G et al. A reactive oxygen species activation mechanism contributes to JS-K-induced apoptosis in human bladder cancer cells. Sci. Rep. 5, 15104 (2015).
  Medline CASGoogle Scholar
• 90 Maciag AE, Chakrapani H, Saavedra JE et al. The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species. J. Pharmacol. Exp. Ther. 336(2), 313–320 (2011).
  Medline CASGoogle Scholar
• 91 Kiziltepe T, Hideshima T, Ishitsuka K et al. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 110(2), 709–718 (2007).
  Medline CASGoogle Scholar
• 92 Qiu M, Ke L, Zhang S, Zeng X, Fang Z, Liu J. JS-K, a GST-activated nitric oxide donor prodrug, enhances chemo-sensitivity in renal carcinoma cells and prevents cardiac myocytes toxicity induced by Doxorubicin. Cancer Chemother. Pharmacol. 80(2), 275–286 (2017).
  Medline CASGoogle Scholar
• 93 Heckler M, Osterberg N, Guenzle J et al. The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation. Tumour Biol. 39(6), 1393385742 (2017).
  Google Scholar
• 94 Shami PJ, Maciag AE, Eddington JK et al. JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C). Leuk. Res. 33(11), 1525–1529 (2009).
  Medline CASGoogle Scholar
• 95 Liu J, Li C, Qu W et al. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation. Mol. Cancer Ther. 3(6), 709–714 (2004).
  Medline CASGoogle Scholar
• 96 Kang F, Ai Y, Zhang Y, Huang Z. Design and synthesis of new hybrids from 2-cyano-3,12-dioxooleana- 9-dien-28-oic acid and O(2)-(2,4-dinitrophenyl) diazeniumdiolate for intervention of drug-resistant lung cancer. Eur. J. Med. Chem. 149, 269–280 (2018).
  Medline CASGoogle Scholar
• 97 Li Q, Zou P, Sun J, Chen L. O(2)-(2,4-dinitrophenyl)diazeniumdiolates derivatives: design, synthesis, cytotoxic evaluation and reversing MDR in MCF-7/ADR cells. Eur. J. Med. Chem. 143, 732–744 (2018).
  Medline CASGoogle Scholar
• 98 Kogias E, Osterberg N, Baumer B et al. Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-pi-activated nitric oxide donor PABA/NO in malignant gliomas. Int. J. Cancer 130(5), 1184–1194 (2012).
  Medline CASGoogle Scholar
• 99 Ren Z, Gu X, Lu B et al. Anticancer efficacy of a nitric oxide-modified derivative of bifendate against multidrug-resistant cancer cells. J. Cell Mol. Med. 20(6), 1095–1105 (2016).
  Medline CASGoogle Scholar
• 100 Guo Y, Wang Y, Li H et al. Novel nitric oxide donors of phenylsulfonylfuroxan and 3-benzyl coumarin derivatives as potent antitumor agents. ACS Med. Chem. Lett. 9(5), 502–506 (2018).
  Medline CASGoogle Scholar
• 101 Rajendra PV, Deepak RG, Kathmann I, Amareswararao M, Peters GJ. Nitric oxide releasing acridone carboxamide derivatives as reverters of doxorubicin resistance in MCF7/Dx cancer cells. Bioorg. Chem. 64, 51–58 (2016).
  MedlineGoogle Scholar
• 102 Rapozzi V, Della PE, Bonavida B. Dual roles of nitric oxide in the regulation of tumor cell response and resistance to photodynamic therapy. Redox Biol. 6, 311–317 (2015).
  Medline CASGoogle Scholar
• 103 Bonavida B, Baritaki S. Inhibition of epithelial-to-mesenchymal transition (EMT) in cancer by nitric oxide: pivotal roles of nitrosylation of NF-kappaB, YY1 and Snail. For. Immunopathol. Dis. Therap. 3(2), 125–133 (2012).
  MedlineGoogle Scholar
• 104 Bonavida B, Baritaki S. Dual role of NO donors in the reversal of tumor cell resistance and EMT: downregulation of the NF-kappaB/Snail/YY1/RKIP circuitry. Nitric Oxide 24(1), 1–7 (2011).
  Medline CASGoogle Scholar
• 105 Nagai H, Yasuda H, Hatachi Y et al. Nitric oxide (NO) enhances pemetrexed cytotoxicity via NOcGMP signaling in lung adenocarcinoma cells in vitro and in vivo. Int. J. Oncol. 41(1), 24–30 (2012).
  Medline CASGoogle Scholar
• 106 Frederiksen LJ, Sullivan R, Maxwell LR et al. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin. Cancer Res. 13(7), 2199–2206 (2007).
  Medline CASGoogle Scholar
• 107 Muir CP, Adams MA, Graham CH. Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells. Breast Cancer Res. Treat. 96(2), 169–176 (2006).
  Medline CASGoogle Scholar
• 108 Maksimovic-Ivanic D, Mijatovic S, Miljkovic D et al. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. Mol. Cancer Ther. 8(5), 1169–1178 (2009).
  Medline CASGoogle Scholar
• 109 Rothweiler F, Michaelis M, Brauer P et al. Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia 12(12), 1023–1030 (2010).
  Medline CASGoogle Scholar
• 110 Donia M, Maksimovic-Ivanic D, Mijatovic S et al. In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle 10(3), 492–499 (2011).
  Medline CASGoogle Scholar
• 111 Stewart GD, Nanda J, Brown DJ, Riddick AC, Ross JA, Habib FK. NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int. J. Cancer 124(1), 223–232 (2009).
  Medline CASGoogle Scholar
• 112 Bratasz A, Selvendiran K, Wasowicz T et al. NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols. J. Transl. Med. 6, 9 (2008).
  MedlineGoogle Scholar
• 113 Gazzano E, Chegaev K, Rolando B et al. Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins. Bioorg. Med. Chem. 24(5), 967–975 (2016).
  Medline CASGoogle Scholar
• 114 Pedrini I, Gazzano E, Chegaev K et al. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells. Mol. Pharm. 11(9), 3068–3079 (2014).
  Medline CASGoogle Scholar
• 115 Gazzano E, Rolando B, Chegaev K et al. Folate-targeted liposomal nitrooxy-doxorubicin: an effective tool against P-glycoprotein-positive and folate receptor-positive tumors. J. Control. Release 270, 37–52 (2018).
  Medline CASGoogle Scholar
• 116 Riganti C, Rolando B, Kopecka J et al. Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance. Mol. Pharm. 10(1), 161–174 (2013).
  Medline CASGoogle Scholar
• 117 Chegaev K, Fraix A, Gazzano E et al. Light-regulated NO release as a novel strategy to overcome doxorubicin multidrug resistance. ACS Med. Chem. Lett. 8(3), 361–365 (2017).
  Medline CASGoogle Scholar
• 118 Kilburn KH, Thrasher JD, Gray MR. Low-level hydrogen sulfide and central nervous system dysfunction. Toxicol. Ind. Health 26(7), 387–405 (2010).
  Medline CASGoogle Scholar
• 119 Lee ZW, Deng LW. Role of H₂S donors in cancer biology. Handb. Exp. Pharmacol. 230, 243–265 (2015).
  Medline CASGoogle Scholar
• 120 Wu D, Si W, Wang M, Lv S, Ji A, Li Y. Hydrogen sulfide in cancer: friend or foe? Nitric Oxide 50, 38–45 (2015).
  Medline CASGoogle Scholar
• 121 Zhen Y, Pan W, Hu F et al. Exogenous hydrogen sulfide exerts proliferation/anti-apoptosis/angiogenesis/migration effects via amplifying the activation of NF-kappaB pathway in PLC/PRF/5 hepatoma cells. Int. J. Oncol. 46(5), 2194–2204 (2015).
  Medline CASGoogle Scholar
• 122 Yang CT, Chen L, Xu S, Day JJ, Li X, Xian M. Recent development of hydrogen sulfide releasing/stimulating reagents and their potential applications in cancer and glycometabolic disorders. Front. Pharmacol. 8, 664 (2017).
  MedlineGoogle Scholar
• 123 Untereiner AA, Pavlidou A, Druzhyna N, Papapetropoulos A, Hellmich MR, Szabo C. Drug resistance induces the upregulation of H2S-producing enzymes in HCT116 colon cancer cells. Biochem. Pharmacol. 149, 174–185 (2018).
  Medline CASGoogle Scholar
• 124 Untereiner AA, Olah G, Modis K, Hellmich MR, Szabo C. H2S-induced S-sulfhydration of lactate dehydrogenase a (LDHA) stimulates cellular bioenergetics in HCT116 colon cancer cells. Biochem. Pharmacol. 136, 86–98 (2017).
  Medline CASGoogle Scholar
• 125 Hellmich MR, Szabo C. Hydrogen sulfide and cancer. Handb. Exp. Pharmacol. 230, 233–241 (2015).
  Medline CASGoogle Scholar
• 126 Szabo C, Coletta C, Chao C et al. Tumor-derived hydrogen sulfide, produced by cystathionine-beta-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. Proc. Natl Acad. Sci. USA 110(30), 12474–12479 (2013).
  Medline CASGoogle Scholar
• 127 Ma Y, Yan Z, Deng X et al. Anticancer effect of exogenous hydrogen sulfide in cisplatinresistant A549/DDP cells. Oncol. Rep. 39(6), 2969–2977 (2018).
  Medline CASGoogle Scholar
• 128 Zhao H, Zhu W, Jia L et al. Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy. Br. J. Radiol. 89(1058), 20150665 (2016).
  MedlineGoogle Scholar
• 129 Bae J, Kumazoe M, Yamashita S, Tachibana H. Hydrogen sulphide donors selectively potentiate a green tea polyphenol EGCG-induced apoptosis of multiple myeloma cells. Sci. Rep. 7(1), 6665 (2017).
  MedlineGoogle Scholar
• 130 Frantzias J, Logan JG, Mollat P et al. Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo. Br. J. Pharmacol. 165(6), 1914–1925 (2012).
  Medline CASGoogle Scholar
• 131 Chegaev K, Rolando B, Cortese D et al. H₂S-donating doxorubicins may overcome cardiotoxicity and multidrug resistance. J. Med. Chem. 59(10), 4881–4889 (2016).
  Medline CASGoogle Scholar
• 132 Bigagli E, Luceri C, De Angioletti M et al. New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations. Invest. New Drug 36(6), 985–998 (2018).
  Medline CASGoogle Scholar
• 133 Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med. Oncol. 18(4), 243–259 (2001).
  Medline CASGoogle Scholar
• 134 Maines MD, Abrahamsson PA. Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution. Urology 47(5), 727–733 (1996).
  Medline CASGoogle Scholar
• 135 Loboda A, Jozkowicz A, Dulak J. HO-1/CO system in tumor growth, angiogenesis and metabolism – targeting HO-1 as an anti-tumor therapy. Vascul. Pharmacol. 74, 11–22 (2015).
  Medline CASGoogle Scholar
• 136 Otterbein LE, Hedblom A, Harris C, Csizmadia E, Gallo D, Wegiel B. Heme oxygenase-1 and carbon monoxide modulate DNA repair through ataxia-telangiectasia mutated (ATM) protein. Proc. Natl Acad. Sci. USA 108(35), 14491–14496 (2011).
  Medline CASGoogle Scholar
• 137 Wegiel B, Gallo D, Csizmadia E et al. Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth. Cancer Res. 73(23), 7009–7021 (2013).
  Medline CASGoogle Scholar
• 138 Cascone T, McKenzie JA, Mbofung RM et al. Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy. Cell Metab. 27(5), 977–987 (2018).
  Medline CASGoogle Scholar
• 139 Cui Q, Wen S, Huang P. Targeting cancer cell mitochondria as a therapeutic approach: recent updates. Future Med. Chem. 9(9), 929–949 (2017).
  CASGoogle Scholar
• 140 Zheng DW, Li B, Li CX et al. Photocatalyzing CO₂ to CO for enhanced cancer therapy. Adv. Mater. 29(44), e1703822 (2017).
  Google Scholar
• 141 Bhattacharyya S, Saha S, Giri K et al. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS ONE 8(11), e79167 (2013).
  MedlineGoogle Scholar
• 142 Sen S, Kawahara B, Gupta D et al. Role of cystathionine beta-synthase in human breast cancer. Free Radic. Biol. Med. 86, 228–238 (2015).
  Medline CASGoogle Scholar
• 143 Puranik M, Weeks CL, Lahaye D et al. Dynamics of carbon monoxide binding to cystathionine beta-synthase. J. Biol. Chem. 281(19), 13433–13438 (2006).
  Medline CASGoogle Scholar
• 144 Yamamoto T, Takano N, Ishiwata K et al. Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway. Nat. Commun. 5, 3480 (2014).
  MedlineGoogle Scholar
• 145 Al-Owais MM, Scragg JL, Dallas ML et al. Carbon monoxide mediates the anti-apoptotic effects of heme oxygenase-1 in medulloblastoma DAOY cells via K+ channel inhibition. J. Biol. Chem. 287(29), 24754–24764 (2012).
  Medline CASGoogle Scholar
• 146 Bonnet S, Archer SL, Allalunis-Turner J et al. A mitochondria-K⁺ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11(1), 37–51 (2007).
  Medline CASGoogle Scholar
• 147 Kashfi K, Chattopadhyay M, Kodela R. NOS H-sulindac (AV T-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties. Redox Biol. 6, 287–296 (2015).
  Medline CASGoogle Scholar
• 148 Chattopadhyay M, Kodela R, Olson KR, Kashfi K. NOS H-aspirin (NB S-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem. Biophys. Res. Commun. 419(3), 523–528 (2012).
  Medline CASGoogle Scholar
• 149 Verma R, Akhtar Y, Singh S. A review of patents on therapeutic potential and delivery of hydrogen sulfide. Recent Pat. Drug Deliv. Formul. 11(2), 114–123 (2017).
  Medline CASGoogle Scholar
• 150 Yang CT, Chen L, Xu S, Day JJ, Li X, Xian M. Recent development of hydrogen sulfide releasing/stimulating reagents and their potential applications in cancer and glycometabolic disorders. Front. Pharmacol. 8, 664 (2017).
  MedlineGoogle Scholar